What question did this study set out to answer?

Real-World Treatment Outcome of Intravitreal Ranibizumab and Aflibercept in Pseudophakic Eyes with Neovascular Age-Related Macular Degeneration

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates visual outcomes in pseudophakic eyes with neovascular age-related macular degeneration, suggesting effective treatment.

This research aims to assess the long-term outcomes of intravitreal injections of ranibizumab and aflibercept in pseudophakic eyes with neovascular age-related macular degeneration, independent of cataract effects.
Retrospective review of medical records from 93 treatment-naïve pseudophakic patients with neovascular age-related macular degeneration.
Patients received intravitreal injections of ranibizumab or aflibercept between March 2010 and August 2023 and were followed for at least 1 year.
Demographic and clinical variables, including visual acuity, central subfield thickness, and injection counts were analyzed.
Mean visual acuity improved from 51.0 letters at baseline to 57.4 letters at 3 months, then gradually declined to 53.0, 52.9, and 49.7 letters at 1, 2, and 5 years, respectively.
Mean central subfield thickness decreased from 351.2 μm to 230.7 μm at 3 months, then slightly increased to 271.8 μm at 1 year, stable at 271.4 μm at 2 years, and decreased to 251.7 μm by the fifth year.
No significant differences were observed between ranibizumab and aflibercept groups in visual acuity or central subfield thickness.

Choi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates visual outcomes in pseudophakic eyes with neovascular age-related macular degeneration, suggesting effective treatment.